ACTIV-3 Statement 2 Title
Eli Lilly and Company
Eli Lilly says no additional patients hospitalized with #COVID19 will receive its antibody drug, bamlanivimab, after trial data suggested it was unlikely to help. Lilly says it remains confident in the drug’s utility earlier in the course of the disease
The reason the #SARSCoV2 Lilly monoclonal antibody hospital trial was stopped 2 weeks ago was due to futility (not safety)
What does this mean? 1. Early timing of Rx is likely key 2. Doesn't detract from ongoing out-patient, preventative trials potential
Eli Lilly is ending a Phase III trial of its monoclonal antibody in hospitalized patients - because the drug doesn't work for them. Might still help people early in disease.
$LLY Here’s the PR “Based on an updated dataset from the trial reviewed on October 26, no additional COVID-19 patients in this hospitalized setting will receive bamlanivimab...bamlanivimab is unlikely to help hospitalized COVID-19 patients recover”
C. Michael Gibson MD
BREAKING & BIG No more hospitalized patients will receive Eli Lilly's Antibody bamlanivimab to #COVID19 as "bamlanivimab is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease."
$lly antibody fails to help hospitalized patients in NIH trial.
Dr. Suzanne Lentzsch
ACTIV-3 trial using neutralizing mAb for #COVID19 by
was stopped. Data suggest that bamlanivimab is unlikely to help hospitalized COVID-19 patients recover from advanced stage of their disease. ACTIV-3 Statement 2 Title
Rough times for the strategy of "passive immunization" against #COVID19. Negative results in hospitalized patients for both convalescent plasma (PLACID RCT, India) &
's LY-CoV555 (aka bamlanivimab) (ACTIV-3 RCT, US)
Michael David, MD, PhD
"Based on an updated dataset from the trial reviewed on October 26, no additional COVID-19 patients in this hospitalized setting will receive bamlanivimab." - Futility ACTIV-3 Statement 2 Title